Brady Collins
The Hepatitis B vaccine was first approved in the United States in 1981, with a recombinant version becoming available in 1986. In the 1990s, states began mandating the vaccine for all children, and in 1991, it was recommended that all infants and young children receive the vaccine. This shift in policy was influenced by the AIDS outbreak in the early 1980s, the advent of genetically-engineered pharmaceuticals in the late 1980s, and the push for health reform in the early 1990s. The Hepatitis B vaccine is now routinely given to infants in many countries and has been successful in reducing the risk of infection and lowering the incidence of liver cancer.
| Characteristics | Values |
|---|---|
| Year the Hep B vaccine was first approved | 1981 |
| Year a recombinant version of the vaccine came to market | 1986 |
| Year the Hep B vaccine became mandatory for children | 1990s |
| Year the Hep B vaccine was recommended for all infants and young children | 1991 |
| Year the number of reported acute hepatitis B cases remained unchanged | 2019 |
Explore related products
What You'll Learn
Hepatitis B vaccine approved in 1981
The hepatitis B vaccine was first approved in 1981 in the United States. This first vaccine was a plasma-derived, "inactivated" vaccine, developed by Maurice Hilleman and his team. It was manufactured by Merck Pharmaceuticals as "Heptavax", the first commercial hepatitis B vaccine. This first version of the vaccine was heat-treated and involved the collection of blood from hepatitis B virus-infected donors. The pooled blood was then subjected to multiple steps to inactivate the viral particles, including formaldehyde and heat treatment.
In the decade following the vaccine's approval, US health officials issued evolving guidelines on who should receive the vaccine. Initially, this included gay men, injection drug users, and healthcare workers. Later, this was expanded to include hepatitis B-positive women's children, and then, in the 1990s, all newborns. The shift in the perception of hepatitis B in the 1980s and 1990s, from a foreign infection to a deadly killer akin to AIDS, contributed to the widespread adoption of hepatitis B vaccine laws in the 1990s.
In 1986, a second generation of genetically engineered (or DNA recombinant) hepatitis B vaccines was developed. These vaccines, which are synthetically prepared and do not contain blood products, are the ones currently approved and in use in the United States. The blood-derived hepatitis B vaccine was withdrawn from the marketplace in 1986. The recombinant vaccine was developed by scientists at Merck & Co. in collaboration with researchers at the University of California, San Francisco, and the University of Washington. This vaccine was based on a hepatitis B surface antigen (HBsAg) gene inserted into yeast cells, which could produce the noninfectious surface protein without the risk of introducing actual viral DNA.
The hepatitis B vaccine is significant as it is the first anti-cancer vaccine. Chronic hepatitis B and C cause 80% of all liver cancer cases worldwide, so a vaccine that protects against hepatitis B infection can also help prevent liver cancer. The hepatitis B virus was discovered in 1965 by Dr. Baruch Blumberg, who won the Nobel Prize for his discovery.
Vaccination Policy: A Collective Action Problem
You may want to see also
Explore related products
Vaccination of children in the 1990s
The 1990s saw significant developments in childhood vaccination programs, with new vaccines becoming available and changes to recommendations for existing vaccines. The hepatitis B vaccine, for instance, was first approved in 1981 and initially recommended for high-risk groups. However, in the 1990s, it became mandatory for all children in some states, aiming to eliminate hepatitis B transmission. This shift was influenced by the AIDS outbreak, the advent of genetically engineered pharmaceuticals, and a push for health reform.
During this decade, the hepatitis B vaccine faced challenges due to its association with marginalized groups and its portrayal as a deadly infection. To address these concerns, health officials, legislators, and communities advocated for vaccinating children, reflecting the fears and hopes of a nation grappling with AIDS and a flawed healthcare system. By the late 1990s and early 2000s, perceptions of the hepatitis B vaccine evolved again, influenced by shifting cultural and scientific understandings.
In Canada, two new Haemophilus influenzae b (HIb) conjugate vaccines were licensed in 1991 for young infants, adding to the existing vaccines for diphtheria, tetanus, pertussis, measles, mumps, rubella, and polio. The Canadian Paediatric Society and the National Advisory Committee on Immunization recommended combining the HIb vaccine with diphtheria/pertussis/tetanus and oral polio vaccines to simplify the immunization schedule. However, this presented technical challenges and concerns about stability and performance.
By the 1990s, childhood vaccination had become more complex, with children receiving multiple shots by the age of two. This complexity prompted the development of combination vaccines to reduce the number of injections. The DTaP and MMR vaccines were combined, and research was underway to include hepatitis B and Haemophilus influenzae type b (Hib) in broader combinations. These efforts aimed to improve vaccine convenience, efficacy, and accessibility for children.
Smallpox Vaccination: The US History and End Date
You may want to see also
Explore related products
Genetically engineered vaccines in the late 1980s
In the late 1980s, the hepatitis B vaccine was approved for use in the United States. This was the first genetically engineered vaccine to be approved for use in humans. The development of this vaccine was a significant milestone in the history of vaccination and genetic engineering.
The hepatitis B vaccine was created using recombinant DNA techniques, which involve inserting a selected gene from one virus into the genome of another virus. This technology, known as gene splicing, was developed in the early 1980s and allowed scientists to combine the genes of different viruses. The hepatitis B vaccine was also the first anti-cancer vaccine, as it can help prevent liver cancer caused by chronic hepatitis B and C infections.
The approval of the hepatitis B vaccine in 1981 was followed by a decade of evolving guidelines on who should receive the vaccine. Initially, only gay men, injection drug users, and healthcare workers were recommended to be vaccinated. Later, this was expanded to include the children of hepatitis B-positive women and eventually, all newborns. The widespread adoption of hepatitis B vaccine laws in the 1990s reflected the fears and hopes of a nation dealing with the AIDS crisis and a broken healthcare system.
The success of the hepatitis B vaccine demonstrated the potential of genetically engineered vaccines to improve human and animal health. However, despite this early success, no other recombinant engineered vaccine has been approved for use in humans. This is due to the economic realities of vaccine development, as genetically engineered vaccines are more costly to manufacture and require extensive testing and review by regulatory agencies.
In summary, the late 1980s marked a significant period in the development and approval of genetically engineered vaccines, with the hepatitis B vaccine paving the way for future advancements in this field. While there have been challenges and limitations, genetically engineered vaccines continue to hold promise for the future of disease prevention and treatment.
RSV Vaccination: One Shot Deal?
You may want to see also
Explore related products
Hepatitis B vaccine laws in the 1990s
The Hepatitis B vaccine was first approved in the United States in 1981. In the following decade, US health officials issued evolving guidelines on who should receive the vaccine, initially recommending it for gay men, injection drug users, and healthcare workers, and later for hepatitis B-positive women's children and all newborns.
In the 1990s, states' laws that mandated the vaccine for all children were quietly accepted. The widespread adoption of these laws reflected the fears and hopes of a nation stricken by AIDS, briefly enamoured with biotechnology, and struggling with a broken healthcare system. The public perception of hepatitis B had shifted from a foreign infection to a deadly killer akin to AIDS, preventable with cutting-edge scientific technology. This shift in perception, influenced by the outbreak of AIDS, the advent of genetically engineered pharmaceuticals, and a push for health reform, shaped the public image of hepatitis B and its vaccine.
The hepatitis B vaccine was the first anti-cancer vaccine as it helps prevent liver cancer. Worldwide, chronic hepatitis B and C cause 80% of all liver cancer cases, which is the second most common cause of cancer-related deaths. The development of the vaccine was based on the discovery of the "'Australia Antigen" in an Australian Aborigine's blood sample, which reacted with an antibody in the serum of an American haemophilia patient. The virus was discovered in 1965 by Dr Baruch Blumberg, who won the Nobel Prize.
In 1986, research resulted in a second generation of genetically engineered (DNA recombinant) hepatitis B vaccines, which are synthetically prepared and do not contain blood products. These vaccines are approved in the US and it is impossible to get hepatitis B from them.
Vaccines: The Power of Active Immunity
You may want to see also
Explore related products
Hepatitis B vaccination in adults aged 19-59
Hepatitis B is a virus that was discovered in 1965 by Dr. Baruch Blumberg, for which he won the Nobel Prize. In 1969, researchers patented the process for separating and purifying the antigen, forming the basis for developing a vaccine. In 1971, blood banks began using a blood test to screen blood donations, reducing the risk of hepatitis B infections from blood transfusions by 25%. In 1981, the first hepatitis B vaccine was approved in the United States, with a recombinant version becoming available in 1986. This vaccine was the first "anti-cancer" vaccine as hepatitis B is the leading cause of liver cancer worldwide.
In the 1980s and 1990s, the image of hepatitis B shifted from a foreign infection to a deadly killer, akin to AIDS. This shift in perception, coupled with the outbreak of AIDS, the advent of genetically-engineered pharmaceuticals, and the push for health reforms, led to the mandatory vaccination of children during this period. However, in the 2000s, anti-vaccine sentiments emerged, targeting the hepatitis B vaccine as an emblem of immunisation policy excesses.
Today, hepatitis B vaccination is recommended for all newborns, children up to the age of 18, and adults aged 19-59. Adults aged 60 and older who are at high risk for infection are also advised to receive the vaccine. The CDC recommends three doses for people aged 19 and younger, and three doses for those aged 20 and older. Adults on dialysis or predialysis should receive three doses of the dialysis formulation, while adults on hemodialysis should receive four doses.
The two-dose HepB vaccine, Heplisav-B, was approved by the FDA in 2017 and recommended by the ACIP in 2018. This vaccine is administered as two doses given one month apart and is suitable for adults aged 18 and older. The hepatitis B vaccine is considered safe during pregnancy and breastfeeding and has not been linked to Guillain-Barré syndrome. It is available by itself or in combination with other vaccines.
Hepatitis B vaccination is crucial, as everyone is at some risk of infection during their lifetime. Certain groups, such as sexually active individuals with multiple partners, those seeking treatment for sexually transmitted infections, and healthcare workers, are at an increased risk of exposure. The vaccine provides protection against a preventable chronic liver disease, and testing is available to confirm successful immunisation.
The Mystery of Hand, Foot and Mouth: Vaccine Elusive
You may want to see also
Frequently asked questions
The Hep B vaccine became mandatory for children in the US in the 1990s.
The first Hep B vaccine was approved in the US in 1981.
The original strategy, starting in the early 1980s, was to vaccinate only those at highest risk (e.g. healthcare workers, patients on dialysis, and intravenous drug users).
The vaccination strategy changed in 1991, when all infants and young children were recommended to receive the Hep B vaccine.
As of 2022, the Advisory Committee on Immunization Practices has recommended universal Hep B vaccination for adults aged 19-59.
